Shun Lu

57PUBLICATIONS

223CO-AUTHORS

Predictive and prognostic markersMedical bacteriologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsRadiation therapy

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (57)

Sort by Publication Date:

|Jun 26, 2026

Early Detriment Analysis of First-Line Nivolumab plus Ipilimumab-Based Therapy in Patients with Metastatic Non-Small Cell Lung Cancer.

|Jun 16, 2026

Author Correction: A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice.

|Jun 02, 2026

MYBL2 impedes cisplatin sensitivity through suppressing GSDME-mediated pyroptosis in lung adenocarcinoma.

|May 25, 2026

TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with <i>EGFR</i>-mutated locally advanced or metastatic non-small cell lung cancer.

|Mar 10, 2026

A clinic-responder-derived defined microbial consortium enhances anti-PD-1 immunotherapy efficacy in mice.

Haiyan Zhou, Ruiming Sun, Xiaoqun Nie

|Jun 18, 2025

OX40-heparan sulfate binding facilitates CAR T cell penetration into solid tumors in mice.

Huihui Zhang, Runbo Zhong, Wanting Wang

Pageof 10

Frequent Collaborators

Nicolas Girard

Xiaokuan Zhu

James Chih-Hsin Yang

Byoung Chul Cho

Luis Paz-Ares

Ziming Li

Ross Andrew Soo

Yi-Long Wu

Chengzhi Zhou

Dingzhi Huang

Frequent Collaborators

Nicolas Girard

Xiaokuan Zhu

James Chih-Hsin Yang

Byoung Chul Cho